{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T18:57:30Z","timestamp":1791917850122,"version":"4.3.4"},"reference-count":89,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T00:00:00Z","timestamp":1727308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"JSPS KAKENHI","award":["JP22K08336"],"award-info":[{"award-number":["JP22K08336"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>IgA nephropathy (IgAN) is characterized by immune-mediated glomerulonephritis, with the accumulation of galactose-deficient IgA1 (Gd-IgA1) in the glomeruli and increased levels of circulating Gd-IgA1 and Gd-IgA1-containing immune complexes. An incomplete understanding of the underlying mechanisms and differences in clinical and pathological features between individuals and ethnicities has contributed to the lack of established treatments for IgAN. A tumor necrosis factor (TNF) family member, a proliferation-inducing ligand (APRIL), is a crucial cytokine essential for the generation and survival of plasma cells. Recent studies demonstrated that APRIL is a pivotal mediator in the production of Gd-IgA1 in IgAN. As our understanding of the autoimmune pathogenesis underlying IgAN has improved, various pharmacological therapeutic targets, including APRIL antagonists, have emerged. Preliminary results showed that APRIL-targeting agents effectively reduced proteinuria and Gd-IgA1 levels without significantly increasing adverse events, indicating their potential as novel therapeutic agents for IgAN. In the present review, we discuss the current understanding of the role of APRIL in the pathogenesis of IgAN and novel therapeutic strategies focusing on APRIL-targeting agents for IgAN. APRIL inhibitors may offer new hope to patients with IgAN.<\/jats:p>","DOI":"10.3390\/ijms251910340","type":"journal-article","created":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T06:55:52Z","timestamp":1727333752000},"page":"10340","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["New Insights and Future Perspectives of APRIL in IgA Nephropathy"],"prefix":"10.3390","volume":"25","author":[{"given":"Masahiro","family":"Muto","sequence":"first","affiliation":[{"name":"Department of Nephrology, Juntendo University Urayasu Hospital, Chiba 279-0021, Japan"},{"name":"Department of Nephrology, Juntendo University Faculty of Medicine, Tokyo 113-8421, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1901-2111","authenticated-orcid":false,"given":"Hitoshi","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Juntendo University Urayasu Hospital, Chiba 279-0021, Japan"},{"name":"Department of Nephrology, Juntendo University Faculty of Medicine, Tokyo 113-8421, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Juntendo University Urayasu Hospital, Chiba 279-0021, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/ndt\/gfq665","article-title":"The incidence of primary glomerulonephritis worldwide: A systematic review of the literature","volume":"26","author":"McGrogan","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ekir.2017.08.008","article-title":"Life Expectancy for Patients From the Southeastern United States With IgA Nephropathy","volume":"3","author":"Hastings","year":"2017","journal-title":"Kidney Int. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Moriyama, T., Tanaka, K., Iwasaki, C., Oshima, Y., Ochi, A., Kataoka, H., Itabashi, M., Takei, T., Uchida, K., and Nitta, K. (2014). Prognosis in IgA Nephropathy: 30-Year Analysis of 1,012 Patients at a Single Center in Japan. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0091756"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1681\/ASN.2011050464","article-title":"The Pathophysiology of IgA Nephropathy","volume":"22","author":"Suzuki","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.34067\/KID.0002972021","article-title":"The Phenotypic Difference of IgA Nephropathy and its Race\/Gender-dependent Molecular Mechanisms","volume":"2","author":"Suzuki","year":"2021","journal-title":"Kidney360"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e194772","DOI":"10.1001\/jamanetworkopen.2019.4772","article-title":"Association Between Tonsillectomy and Outcomes in Patients With Immunoglobulin A Nephropathy","volume":"2","author":"Hirano","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"sfad294","DOI":"10.1093\/ckj\/sfad294","article-title":"Clinicopathological prognostic stratification for proteinuria and kidney survival in IgA nephropathy: A Japanese prospective cohort study","volume":"17","author":"Koike","year":"2023","journal-title":"Clin. Kidney J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 Clinical practice guideline for the management of glomerular diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1001\/jama.2022.5368","article-title":"Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: The TESTING randomized clinical trial","volume":"327","author":"Lv","year":"2022","journal-title":"JAMA"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.kint.2023.01.018","article-title":"Glucocorticoids for IgA nephropathy-pro","volume":"103","author":"Zhang","year":"2023","journal-title":"Kidney Int."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1681\/ASN.2022020201","article-title":"Further Evidence for the Mucosal Origin of Pathogenic IgA in IgA Nephropathy","volume":"33","author":"Cheung","year":"2022","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Knoppova, B., Reily, C., Maillard, N., Rizk, D.V., Moldoveanu, Z., Mestecky, J., Raska, M., Renfrow, M.B., Julian, B.A., and Novak, J. (2016). The Origin and Activities of IgA1-Containing Immune Complexes in IgA Nephropathy. Front. Immunol., 7.","DOI":"10.3389\/fimmu.2016.00117"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s00281-021-00871-y","article-title":"The mucosal immune system and IgA nephropathy","volume":"43","author":"Gesualdo","year":"2021","journal-title":"Semin. Immunopathol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.amjms.2020.10.003","article-title":"IgA Nephropathy: An Interesting Autoimmune Kidney Disease","volume":"361","author":"Rajasekaran","year":"2020","journal-title":"Am. J. Med. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1182\/blood-2006-08-041772","article-title":"TACI regulates IgA production by APRIL in collaboration with HSPG","volume":"109","author":"Sakurai","year":"2006","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/ni.1914","article-title":"The transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptor MyD88","volume":"11","author":"He","year":"2010","journal-title":"Nat. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1182\/blood-2007-09-110858","article-title":"APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells","volume":"111","author":"Belnoue","year":"2008","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jaut.2018.10.016","article-title":"The role of APRIL-A proliferation inducing ligand-In autoimmune diseases and expectations from its targeting","volume":"95","author":"Baert","year":"2018","journal-title":"J. Autoimmun."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2003-02-0540","article-title":"Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway","volume":"103","author":"Kern","year":"2004","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1182\/blood-2006-04-015958","article-title":"Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL","volume":"109","author":"Chiu","year":"2006","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1002\/eji.200737210","article-title":"Specific TLR ligands regulate APRIL secretion by dendritic cells in a PKR-dependent manner","volume":"37","author":"Hardenberg","year":"2007","journal-title":"Eur. J. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/ni.1981","article-title":"Eosinophils are required for the maintenance of plasma cells in the bone marrow","volume":"12","author":"Chu","year":"2011","journal-title":"Nat. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1182\/blood-2011-01-332940","article-title":"Production of the plasma-cell survival factor a proliferation-inducing ligand (APRIL) peaks in myeloid precursor cells from human bone marrow","volume":"118","author":"Matthes","year":"2011","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/ni.2194","article-title":"B cell\u2013helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen","volume":"13","author":"Puga","year":"2011","journal-title":"Nat. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/embo-reports\/kve198","article-title":"Biologically active APRIL is secreted following intracellular processing in the Golgi apparatus by furin convertase","volume":"2","author":"Albar","year":"2001","journal-title":"Embo Rep."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Maia, S., Pelletier, M., Ding, J., Hsu, Y.-M., Sallan, S.E., Rao, S.P., Nadler, L.M., and Cardoso, A.A. (2011). Aberrant Expression of Functional BAFF-System Receptors by Malignant B-Cell Precursors Impacts Leukemia Cell Survival. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0020787"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/eji.201040591","article-title":"Mutation of the BAFF furin cleavage site impairs B-cell homeostasis and antibody responses","volume":"41","author":"Bossen","year":"2010","journal-title":"Eur. J. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1021\/bi048227k","article-title":"Selectivity of BAFF\/BLyS and APRIL for Binding to the TNF Family Receptors BAFFR\/BR3 and BCMA","volume":"44","author":"Day","year":"2005","journal-title":"Biochemistry"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev.immunol.21.120601.141152","article-title":"BAFF and APRIL: A Tutorial on B Cell Survival","volume":"21","author":"Mackay","year":"2003","journal-title":"Annu. Rev. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1084\/jem.20032000","article-title":"TACI and BAFF-R mediate isotype switching in B cells","volume":"201","author":"Castigli","year":"2005","journal-title":"J. Exp. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.jaci.2007.06.012","article-title":"Transmembrane activator and calcium modulator and cyclophilin ligand interactor enhances CD40-driven plasma cell differentiation","volume":"120","author":"Castigli","year":"2007","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1182\/blood-2007-09-110874","article-title":"TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts","volume":"111","author":"Bossen","year":"2008","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.4049\/jimmunol.1001120","article-title":"The structure of the TNFRSF13C promoter enables differential expression of BAFF-R during B cell ontogeny and terminal differentiation","volume":"185","author":"Mihalcik","year":"2010","journal-title":"J. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"807","DOI":"10.4049\/jimmunol.173.2.807","article-title":"B Cell-Activating Factor Belonging to the TNF Family (BAFF)-R Is the Principal BAFF Receptor Facilitating BAFF Costimulation of Circulating T and B Cells","volume":"173","author":"Ng","year":"2004","journal-title":"J. Immunol."},{"key":"ref_35","first-page":"795","article-title":"BAFF is involved in the pathogenesis of IgA nephropathy by activating the TRAF6\/NF-\u03baB signaling pathway in glomerular mesangial cells","volume":"21","author":"Cao","year":"2020","journal-title":"Mol. Med. Rep."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Zheng, N., Wang, D., Ming, H., Zhang, H., and Yu, X. (2015). BAFF promotes proliferation of human mesangial cells through interaction with BAFF-R. BMC Nephrol., 16.","DOI":"10.1186\/s12882-015-0064-y"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1177\/0961203317717083","article-title":"Renal tubular epithelial cell-derived BAFF expression mediates kidney damage and correlates with activity of proliferative lupus nephritis in mouse and men","volume":"27","author":"Schwarting","year":"2017","journal-title":"Lupus"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1600-0609.2009.01262.x","article-title":"APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop","volume":"83","author":"Moreaux","year":"2009","journal-title":"Eur. J. Haematol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/ni.1666","article-title":"Tonic B cell antigen receptor signals supply an NF-kappaB substrate for prosurvival BLyS signaling","volume":"9","author":"Stadanlick","year":"2008","journal-title":"Nat. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/ng.1047","article-title":"A genome-wide association study in Han Chinese identifies multiple susceptibility loci for IgA nephropathy","volume":"44","author":"Yu","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1038\/s41588-023-01422-x","article-title":"Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy","volume":"55","author":"Kiryluk","year":"2023","journal-title":"Nat. Genet."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1172\/JCI45563","article-title":"Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy","volume":"121","author":"McCarthy","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/ndt\/gfaa264","article-title":"High levels of gut-homing immunoglobulin A + B lymphocytes support the pathogenic role of intestinal mucosal hyperresponsiveness in immunoglobulin A nephropathy patients","volume":"36","author":"Sallustio","year":"2021","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1681\/ASN.2016050496","article-title":"Toll-Like Receptor 9 Stimulation Induces Aberrant Expression of a Proliferation-Inducing Ligand by Tonsillar Germinal Center B Cells in IgA Nephropathy","volume":"28","author":"Muto","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.4049\/jimmunol.172.5.3268","article-title":"Lymphoma B Cells Evade Apoptosis through the TNF Family Members BAFF\/BLyS and APRIL","volume":"172","author":"He","year":"2004","journal-title":"J. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"5206","DOI":"10.1182\/blood-2008-09-179762","article-title":"A proliferation-inducing ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinase\u2013regulated mammalian target of rapamycin activation","volume":"113","author":"Gupta","year":"2009","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1002\/art.24628","article-title":"Systemic activation of the immune system induces aberrant BAFF and APRIL expression in B cells in patients with systemic lupus erythematosus","volume":"60","author":"Chu","year":"2009","journal-title":"Arthritis Rheum."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.kint.2019.08.022","article-title":"TLR9 activation induces aberrant IgA glycosylation via APRIL- and IL-6\u2013mediated pathways in IgA nephropathy","volume":"97","author":"Makita","year":"2019","journal-title":"Kidney Int."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.kint.2019.01.031","article-title":"A Proliferation Inducing Ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy","volume":"96","author":"Myette","year":"2019","journal-title":"Kidney Int."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1681\/ASN.2015060677","article-title":"The Role of TNF Superfamily Member 13 in the Progression of IgA Nephropathy","volume":"27","author":"Han","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"683","DOI":"10.5301\/jn.5000218","article-title":"Serum BAFF is elevated in patients with IgA nephropathy and associated with clinical and histopathological features","volume":"26","author":"Xin","year":"2012","journal-title":"J. Nephrol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.clim.2007.11.003","article-title":"Increase in B-cell-activation factor (BAFF) and IFN-gamma productions by tonsillar mononuclear cells stimulated with deoxycytidyl-deoxyguanosine oligodeoxynucleotides (CpG-ODN) in patients with IgA nephropathy","volume":"126","author":"Goto","year":"2008","journal-title":"Clin. Immunol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nature06005","article-title":"Unravelling the pathogenesis of inflammatory bowel disease","volume":"448","author":"Xavier","year":"2007","journal-title":"Nature"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"S180","DOI":"10.1016\/j.ekir.2022.01.421","article-title":"POS-399 Anti-BAFF antibody is effective to inhibit the production of immunoglobulins, but not nephritogenic IgA in murine IgA nephropathy","volume":"7","author":"Kim","year":"2022","journal-title":"Kidney Int. Rep."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","article-title":"Intensive Supportive Care plus Immunosuppression in IgA Nephropathy","volume":"373","author":"Rauen","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2017.9362","article-title":"Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: The TESTING randomized clinical trial","volume":"318","author":"Lv","year":"2017","journal-title":"JAMA"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1007\/s10157-023-02396-0","article-title":"Committee of Clinical Practical Guideline for IgA Nephropathy 2020 Current treatment status of IgA nephropathy in Japan: A questionnaire survey","volume":"27","author":"Matsuzaki","year":"2023","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1016\/j.ekir.2020.08.009","article-title":"Why target the gut to treat IgA nephropathy?","volume":"5","author":"Barratt","year":"2020","journal-title":"Kidney Int. Rep."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.semnephrol.2018.05.020","article-title":"The Gut-Renal Connection in IgA Nephropathy","volume":"38","author":"Coppo","year":"2018","journal-title":"Semin. Nephrol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/ng.3118","article-title":"Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens","volume":"46","author":"Kiryluk","year":"2014","journal-title":"Nat. Genet."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s10038-019-0699-9","article-title":"Identification of susceptibility locus shared by IgA nephropathy and inflammatory bowel disease in a Chinese Han population","volume":"65","author":"Shi","year":"2019","journal-title":"J. Hum. Genet."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1681\/ASN.2020060848","article-title":"Inflammatory Bowel Disease Is More Common in Patients with IgA Nephropathy and Predicts Progression of ESKD: A Swedish Population-Based Cohort Study","volume":"32","author":"Rehnberg","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"704","DOI":"10.2215\/CJN.0000000000000457","article-title":"Association of inflammatory bowel disease with incident immunoglobulin A nephropathy","volume":"19","author":"Nakayama","year":"2024","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/0-387-33778-4_10","article-title":"The B-cell system in inflammatory bowel disease","volume":"579","author":"Brandtzaeg","year":"2006","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","article-title":"Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial","volume":"402","author":"Lafayette","year":"2023","journal-title":"Lancet"},{"key":"ref_67","first-page":"803","article-title":"Pharmacokinetics of Budesonide (EntocortTM EC) Capsules for Crohn\u2019s Disease","volume":"43","author":"Andersson","year":"2004","journal-title":"Clin. Pharmacokinet."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.kint.2023.11.003","article-title":"Targeted-release budesonide modifies key pathogenic biomarkers in immunoglobulin A nephropathy: Insights from the NEFIGAN trial","volume":"105","author":"Wimbury","year":"2024","journal-title":"Kidney Int."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1681\/ASN.2016060640","article-title":"A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction","volume":"28","author":"Lafayette","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.4049\/jimmunol.1101230","article-title":"Characterization of a Transitional Preplasmablast Population in the Process of Human B Cell to Plasma Cell Differentiation","volume":"187","author":"Jourdan","year":"2011","journal-title":"J. Immunol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"5181","DOI":"10.1182\/blood-2010-01-266536","article-title":"Steady-state generation of mucosal IgA+ plasmablasts is not abrogated by B-cell depletion therapy with rituximab","volume":"116","author":"Mei","year":"2010","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1681\/ASN.2017040367","article-title":"Targeting B Cells and Plasma Cells in Glomerular Diseases: Translational Perspectives","volume":"29","author":"Schrezenmeier","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.ekir.2018.03.001","article-title":"Bortezomib for Reduction of Proteinuria in IgA Nephropathy","volume":"3","author":"Hartono","year":"2018","journal-title":"Kidney Int. Rep."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2305635","article-title":"A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy","volume":"390","author":"Mathur","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1136\/annrheumdis-2018-213032","article-title":"Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): Results from a randomised, double-blind, placebo-controlled trial","volume":"77","author":"Merrill","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_76","first-page":"4B","article-title":"FR-PO1128 effects of blisibimod, a selective inhibitor of B-cell activating factor, in patients with IgA nephropathy","volume":"27","author":"Barratt","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Kaegi, C., Steiner, U.C., Wuest, B., Crowley, C., and Boyman, O. (2020). Systematic Review of Safety and Efficacy of Atacicept in Treating Immune-Mediated Disorders. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.00433"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/j.ekir.2022.05.017","article-title":"Randomized Phase II JANUS Study of Atacicept in Patients With IgA Nephropathy and Persistent Proteinuria","volume":"7","author":"Barratt","year":"2022","journal-title":"Kidney Int. Rep."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.kint.2024.03.012","article-title":"A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy","volume":"105","author":"Lafayette","year":"2024","journal-title":"Kidney Int."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s40265-021-01591-1","article-title":"Telitacicept: First Approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"105704","DOI":"10.1016\/j.ejps.2021.105704","article-title":"Pharmacokinetics analysis based on target-mediated drug distribution for RC18, a novel BLyS\/APRIL fusion protein to treat systemic lupus erythematosus and rheumatoid arthritis","volume":"159","author":"Yao","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ekir.2022.12.014","article-title":"Randomized Phase 2 Trial of Telitacicept in Patients With IgA Nephropathy With Persistent Proteinuria","volume":"8","author":"Lv","year":"2022","journal-title":"Kidney Int. Rep."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.ekir.2024.01.003","article-title":"Effect of telitacicept on circulating Gd-IgA1 and IgA-containing immune complexes in IgA nephropathy","volume":"9","author":"Zan","year":"2024","journal-title":"Kidney Int. Rep."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"gfae069-0431","DOI":"10.1093\/ndt\/gfae069.431","article-title":"#1342 Updated results from the RUBY-3 study of povetacicept, an enhanced dual BAFF\/APRIL antagonist, in autoantibody-associated glomerulonephritis","volume":"39","author":"Madan","year":"2024","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_85","first-page":"i145","article-title":"MO212: Updated interim results of a phase 1\/2 study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and clinical activity of BION-1301 in patients with IgA nephropathy","volume":"37","author":"Barratt","year":"2022","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"S280","DOI":"10.1016\/j.ekir.2023.02.632","article-title":"WCN23-1175 updated interim results of a phase 1\/2 study of BION-1301 in patients with IgA nephropathy","volume":"8","author":"Barratt","year":"2023","journal-title":"Kidney Int. Rep."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"S280","DOI":"10.1016\/j.ekir.2023.02.631","article-title":"WCN23-1107 a phase 1\/2 multicenter study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamis of BION-1301 in healthy volunteers and adults with iga nephropathy","volume":"8","author":"Kim","year":"2023","journal-title":"Kidney Int. Rep."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Carvalho-Santos, A., Kuhnert, L.R.B., Hahne, M., Vasconcellos, R., Carvalho-Pinto, C.E., and Villa-Verde, D.M.S. (2024). Anti-inflammatory role of APRIL by modulating regulatory B cells in antigen-induced arthritis. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0292028"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1093\/rheumatology\/kev420","article-title":"Exploring BAFF: Its expression, receptors and contribution to the immunopathogenesis of Sj\u00f6gren\u2019s syndrome","volume":"55","author":"Thompson","year":"2016","journal-title":"Rheumatology"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/19\/10340\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:03:45Z","timestamp":1760112225000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/19\/10340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,26]]},"references-count":89,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["ijms251910340"],"URL":"https:\/\/doi.org\/10.3390\/ijms251910340","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,26]]}}}